The long-term treatment of human immunodeficiency virus (HIV)-infected children with combination antiretroviral therapy (cART) requires assessment of potential adverse effects, such as osteoporosis. Longitudinal data on bone mineral density (BMD) in HIV-infected children showed that cumulative treatment with cART had a positive impact on BMD over time.
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The introduction of combination antiretroviral therapy (cART) for the treatment of human immunodeficiency virus (HIV) has substantially increased the life expectancy of HIVinfected adults and children [1] . Simultaneously, noninfectious complications of HIV infection and cART have become increasingly evident [2] . Reduced bone mineral density (BMD), associated with an increased risk of osteoporosis, has been described in HIV-infected patients. BMD is of specific concern in children because peak BMD is not yet reached, with consequences for later in life [3, 4] . In line with adult data, most studies investigating BMD in HIV-infected children detected a lower BMD [5] . However, with regard to the effects of cART on BMD, results are inconclusive, and long-term longitudinal data from a cART-treated HIV-infected pediatric population are lacking [6, 7] . Here we present longitudinal data on BMD obtained by dual-energy x-ray absorptiometry (DEXA-scan) in cART-treated HIV-infected participants of the Pediatric Amsterdam HIV Cohort.
METHODS
All HIV-infected children treated at the Emma Children's Hospital, the Netherlands, between 2002 and 2010 were included in this longitudinal cohort study. HIV infection was diagnosed based on a positive HIV RNA polymerase chain reaction in the first 18 months after birth or by persistence of HIV antibodies after 18 months.
Between 1996 and 2002, standard cART included nelfinavir, lamivudine, and stavudine for the majority of children. From 2002 onward, and based on HIV viral resistance patterns, HIV-infected children received a once daily regimen of stavudine or efavirenz with abacavir, didanosine, and lamivudine (Supplementary Tables 1 and 2) .
Assessments
From 2002, BMD was assessed as part of standard patient care, with intervals of 2-3 years to regularly screen for osteopenia in HIV-infected children. We used DEXA-scans (QDR, 4500W; Hologic Inc, Waltham, MA) of the lumbar spine and left femoral neck to assess BMD, expressed in g/cm 2 . BMD Z-scores were calculated based on reference values supplied by the manufacturer. BMD Z-scores represent the BMD standard deviation from age-and gender-matched uninfected healthy controls. This adjustment for age is essential because BMD increases with age.
Demographic characteristics, HIV-related parameters, cART, and Centers for Disease Control and Prevention (CDC) classification were extracted from the Netherlands HIV Monitoring Foundation database. Body mass index (BMI) was calculated with corresponding BMI Z-scores using the National Center for Health Statistics growth charts (http://www.cdc. gov/growthcharts/clinical_charts.htm).
Before 2001, HIV RNA viral load (HIV VL) was quantified using the NucliSens assay (Biomerieux, Boxtel, the Netherlands). Between 2001 and 2007 the Versant HIV-1 RNA 3.0 Assay (bDNA, Siemens Bayer Diagnostics, Tarrytown, NY) was used; thereafter, the Abbott RealTime HIV-1 assay (Abbott Molecular Inc., Des Plaines, IL) was used. The lower detection limit of the earlier assays was 400 copies/mL, and we used this as the cutoff to define an undetectable VL.
Statistical Analyses
At baseline, which was defined as the time of the first DEXA scan, we determined descriptive statistics for HIV VL and CD4%, nadir CD4%, CDC clinical stage, previous exposure to ART as median, and corresponding interquartile range (IQR) or proportions.
Univariable linear regression analyses with mixed effects were performed to explore associations between BMD Z-score (spinal and femoral) and exposure to ART in general, ART drug classes (ie, protease inhibitor [PI], nucleoside reverse transcriptase inhibitor, and nonnucleoside reverse transcriptase inhibitor), specific ART compounds, BMI, BMI Z-scores, CD4%, CD4 count, HIV VL at time of scan, ethnicity, and gender. We included all significant parameters identified in the univariable analyses in multivariable linear regression analyses. The statistical analyses were performed using the statistical software StataIC 10, 2009 (StataCorp, College Station, TX), and P values of < .05 were considered significant.
RESULTS

Baseline
By August 2010, 66 children were enrolled in the study. The majority (62%) of the HIV-infected children were of black ethnicity (Supplementary Table 1) . At baseline, which was the first assessment, the median age was 6.7 years (IQR, 4.4-10.3). The median CD4 count was 1035 cells/mm³ (IQR, 67-1405), and 58% of the children had an undetectable HIV VL. cART was initiated in 5 children during the study, and 3 children did not receive treatment because they did not meet the criteria to initiate cART. The median duration of ART at baseline was 3.4 years (IQR, 1.5-5.1). Treatment included a PI in 72% of the children. Nelfinavir was the most frequently used nonbackbone antiretroviral compound (57% of the patients) with the longest treatment duration (4.3 years). The median baseline spinal BMD Z-score was -0.9 (IQR, -1.6-0.1), indicating a decreased spinal BMD in HIV-infected children as compared with healthy children. A spinal BMD Z-score of < −2.0, associated with osteopenia and osteoporosis, was detected in 8% of the HIV-infected children [8] .
Longitudinal Data
In total, we obtained 181 DEXA-scans, an average of 2.7 scans (SD 0.2) per child, with an average total follow-up of 4.4 years (SD 0.3) and a maximum follow-up of 7.1 years. In the univariable linear regression analyses, spinal BMD Z-score was not associated with ethnicity (Table 1) . Children with a higher CD4% at the time of the DEXA scan had a significantly higher spinal BMD Z-score, whereas a higher HIV VL was associated with lower spinal BMD Z-scores. The duration of cART was significantly associated with an increase in spinal BMD Z-score (coefficient, 0.08; P < .001). In the multivariable model, adjusting for BMI, CD4%, and HIV VL, duration of cART remained significantly associated with an increase in spinal BMD Z-score (coefficient, 0.05; P = .027; Table 1 ).
To evaluate associations between specific ART compounds and BMD, we used the multivariable linear regression model and substituted duration of cART with duration of treatment with a particular ART class or a specific ART compound while adjusting for CD4%, HIV VL, and BMI (Table 1) . Treatment with nelfinavir and stavudine was associated with an increase in spinal BMD Z-score over age. Nelfinavir and stavudine were given simultaneously; consequently, we could not distinguish between these 2 compounds due to collinearity. Femoral BMD Z-scores were not significantly decreased compared with the reference population at baseline and remained stable during the course of treatment. We did not detect any significant associations between HIV-related parameters and femoral BMD Z-score. Interestingly, children treated with nelfinavir and stavudine also significantly had a higher femoral BMD Z-score over age (coefficient, 0.12; P = .002 and coefficient, 0.10; P = .012). A negative trend was observed between femoral BMD Z-score and treatment with tenofovir or ritonavir-boosted lopinavir, which did not reach significance in the multivariable model.
DISCUSSION
Noninfectious complications of HIV infection and cART, including loss of BMD, have become increasingly evident in HIV-infected individuals [3, 9] . This is of particular concern in children. In our study, using longitudinal data, we show that the spinal BMD Z-score of HIV-infected children was lower compared with healthy controls at study entry. The Zscore increased significantly with longer exposure to cART. A negative effect of HIV-related parameters on BMD, such as a high HIV VL, seemed to be cancelled out by cART. The underlying mechanism behind this observation of a positive impact of cART on BMD is likely related to the inhibition of viral replication by cART and subsequent reduction of immune activation. The initial HIV-induced immune activation alters osteoclast and osteoblast activity, which is critical in regulating bone turnover. Normalization of osteoclast and osteoblast activity as a consequence of cART may allow healthy bone mineralization to occur in HIV-infected children [10] .
In addition to the positive effects of cART on BMD, specific ART drugs, such as tenofovir, have been implicated as having a negative effect on BMD in HIV-infected patients [9] . In our longitudinal study, we did not detect significantly lower spinal and femoral BMD Z-sores in the limited number of children treated with tenofovir or ritonavir-boosted lopinavir. In line with our results, a study comparing a zidovudine, lamiviudine, and efavirenz regimen vs a ritonavir-boosted lopinavir and efavirenz-containing regimen also did not show significant differences, nor did a study investigating long-term effects of tenofovir in children [5, 7] . Remarkably, in our study, treatment with both nelfinavir and stavudine was significantly associated with an increase in the BMD Z-score of the spine and femur over time. It is not possible to attribute a specific effect to either of these 2 drugs because they were prescribed simultaneously. Nevertheless, the increase in spinal BMD observed upon treatment with nelfinavir and stavudine may be explained by successful inhibition of viral replication and reduction of immune activation without direct harmful effects on BMD [11] . We did not specifically explore the association between lipodystrophy and BMD, but our findings do not suggest an important negative impact of stavudine-or nelfinavirassociated lipodystrophy on BMD. The duration is the duration of exposure to antiretroviral therapy (ART) from initiation to the date of the last included dual-energy x-ray absorptiometry scan for each child. For spinal bone mineral density (BMD) Z-score, the multivariable model included body mass index (BMI), CD4%, and viral load; cART was substituted for either an antiretroviral therapy (ART)-class or specific ART compound. For femoral BMD Z-score, the multivariable model included BMI Z-score and ethnicity as well ART compounds significantly associated with femoral neck BMD Z-score in the univariable analyses.
Abbreviations: B, symptomatic; BMI, body mass index; C, AIDS; cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HIV VL, human immunodeficiency virus viral load; MV femoral neck, multivariable linear regression analyses of femoral neck bone mineral density (BMD) Z-score; MV lumbar spine, multivariable linear regression analyses of lumbar spine BMD Z-score; N/A, asymptomatic or acute HIV infection; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; UV femoral neck, univariable linear regression analyses of femoral neck BMD Z-score; UV lumbar spine, univariable linear regression analyses of lumbar spine BMD Z-score.
Our study is limited by changes in treatment strategies over time. For example, tenofovir has only recently been used for pediatric HV infection, and only 13 of the children in our study were exposed to tenofovir. Although our results with regard to tenofovir are reassuring, they do need to be interpreted with caution. Clinicians treating HIV-infected children and adolescents need to carefully monitor BMD when switching to tenofovir or an unexplored ART compound because many of the children or adolescents have not yet attained their peak bone mass and clinical complications may occur in the future [4] . Furthermore, the analyses were not adjusted for factors such as fat redistribution, diet, and use of vitamin D, though none of the children were suspected to have severe vitamin D deficiency.
In conclusion, our results are encouraging and indicate that effective treatment of HIV infection and suppression of viral replication are crucial to the reversal of HIV-induced detrimental effects on BMD in children and may allow normal bone development. Nonetheless, continued caution remains warranted with regard to potential adverse effects on bone when using regimens containing tenofovir, ritonavir-boosted lopinavir, and newly introduced future antiretrovirals.
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